Posted by Michael Wonder on 19 Dec 2024
FDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in paediatric patients
18 December 2024 - Today, the FDA approved remestemcel-L-rknd (Ryoncil, Mesoblast), an allogeneic bone marrow derived mesenchymal stromal cell therapy, for steroid-refractory acute graft versus host disease in paediatric patients 2 months of age and older.
Ryoncil is the first FDA approved mesenchymal stromal cell therapy.
